TRT dose vs. testosterone levels: what bloodwork actually tells you

What did @alphaclubsupps actually say?

The creator returned to his normal TRT dose after a cycle and found his testosterone levels were now higher than expected on the same amount. His total T came in at 47 (nmol/L, presumably) and free T at 1.2, and critically, his hematocrit had not dropped back down post-cycle as he had hoped. He attributed the elevated testosterone response to improved health markers, specifically better insulin sensitivity, lower inflammation, and reduced estradiol. His plan: dose reduction, better hydration, electrolytes, more cardio, and adding daily tadalafil plus continuing resveratrol.

This is a fairly measured, self-aware take from someone managing their own hormones. He is not selling a miracle. He is acknowledging a problem and describing a sensible response. That matters.

Does the science back this up?

Mostly, yes. The claim that metabolic improvements can increase testosterone bioavailability and response is supported by decent evidence, though the creator oversimplifies the mechanism. Hematocrit elevation persisting after a cycle is a well-documented and genuinely serious risk.

Insulin resistance is known to suppress sex hormone-binding globulin (SHBG), which affects free testosterone readings. Studies including Tsai et al. (2004, Diabetes Care) confirmed that insulin resistance lowers SHBG, meaning as insulin sensitivity improves, SHBG may rise or normalize, which can shift how a fixed testosterone dose distributes between bound and free fractions. Separately, chronic inflammation suppresses androgen receptor sensitivity and hypothalamic-pituitary signaling. So yes, fixing metabolic dysfunction can change how your body responds to a stable exogenous testosterone dose. The creator is not wrong here, but he presents it as a straightforward cause and effect when the physiology is more layered than that.

On hematocrit: testosterone reliably stimulates erythropoiesis via EPO signaling in the kidneys. Post-cycle suppression of endogenous testosterone does not immediately reverse elevated red cell mass. Bachman et al. (2010, Journal of Clinical Endocrinology and Metabolism) showed hematocrit increases are dose-dependent and can take months to normalize after dose reduction.

What did they get right, and where are the gaps?

He gets credit for several things. Recommending a dose reduction rather than phlebotomy as a first step is clinically reasonable when the hematocrit elevation is modest and recent. Tadalafil as a daily addition is an interesting choice. There is evidence that PDE5 inhibitors may reduce blood viscosity-related cardiovascular strain, and Vlachopoulos et al. (2005, Journal of the American College of Cardiology) found tadalafil improved arterial stiffness markers. It is not a standard hematocrit management tool, but it is not dangerous, and the cardiovascular rationale is at least grounded in something real.

The gaps are notable, though. He never tells his audience what his actual hematocrit number is. That is a significant omission. The intervention you need at 50 percent is different from what you need at 56 percent. Saying it has not come down is not the same as telling people where it sits. He also references resveratrol as if its clinical benefit in this context is established. The human evidence for resveratrol's effect on erythropoiesis or hematocrit is thin at best.

What should you actually know?

Elevated hematocrit on TRT is one of the more underappreciated risks in the testosterone conversation online. Hematocrit above 54 percent is where most clinical guidelines, including the Endocrine Society's 2018 TRT guidelines, recommend pausing or reducing therapy. Above that threshold, blood viscosity increases in ways that genuinely raise stroke and clotting risk.

The creator's approach of dose reduction plus lifestyle modifications is broadly consistent with first-line guidance for mild-to-moderate elevation. But this is not a DIY situation for most people. Monitoring hematocrit every three to six months on TRT is standard of care, and if it is persistently elevated despite dose reduction, therapeutic phlebotomy or a clinical review is the appropriate next step, not more supplements.

The idea that improved metabolic health can change your response to a stable TRT dose is real and underappreciated. If you started TRT when you were insulin resistant, inflamed, or carrying excess weight, and you have since fixed some of that, your dose may genuinely need reassessment. That is a legitimate clinical point. What it is not is a reason to self-adjust without bloodwork to guide the decision.